4-tert-butyl-N,N-bis(2-chloroethyl)aniline | 64977-11-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-tert-butyl-N,N-bis(2-chloroethyl)aniline
• CAS: 64977-11-3
• 化学式: C₁₄H₂₁Cl₂N
• 分子量: 274.2
• InChiKey: KWUGJGDAMLKTDL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.6
• 重原子数：
  17
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.57
• 拓扑面积：
  3.2
• 氢给体数：
  0
• 氢受体数：
  1

文献信息

• Salinomycin derivatives and therapeutic uses thereof
  申请人：Channel Therapeutics, Inc.

  公开号：US10364253B2

  公开（公告）日：2019-07-30

  The invention relates to salinomycin derivatives such as compounds having the structure of formula (I) or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising a therapeutically effective amount of compounds of formula (I), and the use of compounds of formula (I) for treating or inhibiting progression of cancer. The cancer is selected from the group consisting of breast cancer, pancreatic cancer, and prostate cancer.

  本发明涉及盐霉素衍生物，如具有式（I）结构的化合物或其药学上可接受的盐、包含治疗有效量式（I）化合物的药物组合物，以及式（I）化合物用于治疗或抑制癌症进展的用途。癌症选自由乳腺癌、胰腺癌和前列腺癌组成的组。
• Platinum prodrugs and methods of making and using thereof
  申请人：UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC.

  公开号：US10457700B2

  公开（公告）日：2019-10-29

  Disclosed herein are prodrugs of platinum containing anticancer agents such as cisplatin that contain an alkylating moiety. Upon administration, the prodrugs release the platinum containing anticancer agent and the alkylating agent, which can form an adduct with DNA or can protect the platinum containing agent from removal. The disclosed prodrugs can be used to treat various cancers, including cisplatin resistant cancers.

  本文公开了含有烷基化分子的含铂抗癌剂（如顺铂）的原药。给药时，原药释放出含铂抗癌剂和烷化剂，后者可与 DNA 形成加合物，或保护含铂抗癌剂不被移除。所公开的原药可用于治疗各种癌症，包括顺铂抗药性癌症。
• PLATINUM PRODRUGS AND METHODS OF MAKING AND USING THEREOF
  申请人：UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC.

  公开号：US20180044362A1

  公开（公告）日：2018-02-15

  Disclosed herein are prodrugs of platinum containing anticancer agents such as cisplatin that contain an alkylating moiety. Upon administration, the prodrugs release the platinum containing anticancer agent and the alkylating agent, which can form an adduct with DNA or can protect the platinum containing agent from removal. The disclosed prodrugs can be used to treat various cancers, including cisplatin resistant cancers.